PRD Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PRD Therapeutics, Inc. - overview
Established
2021
Location
Tokyo, -, Japan
Primary Industry
Biotechnology
About
Based in Tokyo, Japan, and founded in 2021, PRD Therapeutics, Inc. , a. k. a.
PRD Therapeutics, researches and develops new lipid metabolism regulators that are effective for rare diseases that cause lipid metabolism abnormalities. In September 2023, PRD Therapeutics, Inc. raised JPY 1. 3 billion in a Series A funding from JAFCO Group, JIC Venture Growth Investments, Mizuho Capital, and SMBC Venture Capital, with participation from Taiho Innovations, LLC.
As of September 2023, Renji Hosoda is the CEO of the company. The company’s product line includes PRD001, an oral lipid-lowering drug for HoFH, which is a rare dyslipidemia with few treatments. PRD001 uses a new mechanism to regulate the blood cholesterol levels of patients. PRD Therapeutics plans to use its proceeds from September 2023 funding to conduct clinical trials for PRD001, a lead compound derived from a fungus that can help treat lipid metabolism problems.
Current Investors
JAFCO Group, SMBC Venture Capital, Mizuho Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Specialty Pharmaceuticals
Website
www.prdtherapeutics.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
PRD Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.